The Quiet Consolidation Nobody Is Talking About
Wound care is not a glamorous corner of medicine. It involves chronic ulcers, diabetic foot wounds, post-surgical complications, and the slow, grinding work of keeping tissue alive. That unglamorous reality has, for decades, kept wound care centers operating as independent, physician-owned practices scattered across mid-size cities and suburban markets. That structure is now changing fast, and the transactions are happening with almost no public attention.
Private equity firms specializing in healthcare rollups have been acquiring regional wound care centers at an accelerating pace over the past several years. The deals are typically small enough to avoid antitrust scrutiny, local enough to escape national press coverage, and structured quietly enough that patients rarely notice until they see a new logo on their billing statement. Behind that logo is almost always a platform company backed by a PE fund with a multi-year exit strategy.
Why Wound Care, Why Now
The basic economics make the sector attractive. Wound care centers generate recurring revenue because chronic wounds – particularly those tied to diabetes, venous insufficiency, and obesity – do not resolve quickly. A patient with a diabetic foot ulcer may require weekly visits for months. That predictability is exactly what PE investors want when building a platform: steady utilization, limited elective-procedure risk, and a patient population that is growing because the underlying conditions driving chronic wounds are becoming more common across the U.S.
Reimbursement is another draw. Outpatient wound care centers typically bill under a facility fee model when hospital-affiliated, and many independent centers have secured agreements with Medicare and major commercial payers that generate healthy margins per visit. When a PE-backed acquirer rolls up enough centers to gain scale, it gains negotiating leverage with payers that a solo practice never had. That leverage translates directly into better contract rates – and the margin gap between a 3-center independent group and a 30-center regional platform is significant enough to justify acquisition premiums.
Physician burnout and succession pressure are doing much of the selling work. Many wound care specialists who built their practices in the 1990s and early 2000s are now approaching retirement age with no internal buyers lined up. Their options are limited: sell to a hospital system (which often means employment contracts with production pressure), bring in a junior partner (which requires capital and patience), or take a check from a PE firm that offers a partial liquidity event and lets them keep running the practice for a few more years. That third option has become the path of least resistance for a growing number of owners.
How the Rollup Structure Works
The typical wound care rollup begins with a platform acquisition – usually a group of three to six centers with strong EBITDA and a physician leader willing to take equity in the new entity. That physician becomes the clinical face of the platform, which makes subsequent acquisitions easier to close because sellers are talking to a peer rather than a financial buyer. The PE firm then runs a geographic tuck-in strategy, buying smaller single-site or two-site practices at lower multiples and absorbing them into the platform’s billing infrastructure, supply contracts, and management layer.
This pattern mirrors what has played out in other outpatient specialty categories – including the consolidation happening among regional ambulatory surgery centers – where the rollup logic depends on compressing administrative costs across a growing site count while the revenue line grows with each acquisition. In wound care, the management layer is relatively thin because clinical protocols are standardized and the technology requirements are modest, which makes the cost compression math work faster than in more complex specialties.
What Changes After the Deal Closes
The first visible change is usually administrative. Billing moves to a centralized system, supply procurement shifts to national contracts, and the scheduling platform gets standardized across all sites. For physicians, this can be a genuine relief – the operational burden that made independent practice exhausting starts to lift. But the relief is often temporary, because the next phase involves productivity benchmarking, and the numbers that come out of that process are not always comfortable for physicians who built their practices around unhurried patient relationships.
Staffing is where the friction tends to surface first. Wound care nurses and wound care certified practitioners are not interchangeable with general clinical staff, and experienced wound care nurses are difficult to recruit and retain. When a PE-backed platform standardizes staffing ratios in the name of margin improvement, it often discovers that wound care throughput depends heavily on experienced judgment calls that do not scale the way a spreadsheet assumes they will. A wound that looks like a routine venous ulcer can turn into a complex case that requires extra chair time. Under volume-based performance metrics, that kind of time is a cost problem.
Patient experience data from markets where wound care consolidation is further along suggests a mixed picture. Some platforms have invested in better electronic health records and point-of-care documentation that actually improves continuity between visits. Others have rotated physicians more aggressively across sites to hit utilization targets, which disrupts the patient-provider continuity that wound healing depends on. Chronic wound care is one of the medical specialties where relationship continuity is not a luxury – it directly affects outcomes, because wound assessment requires knowing what a wound looked like last week and the week before.
The exit horizon creates its own pressure. Most PE funds in the healthcare space operate on a five-to-seven year fund cycle. If an acquirer bought into a wound care platform in 2021 or 2022, the clock is running. The exit options are a sale to a larger strategic buyer, a sale to another PE firm at a higher multiple (a secondary buyout), or, for larger platforms, a public listing. Each of those paths requires the platform to show growth – not just maintained performance. That growth requirement does not always align with what a chronic wound patient needs from their care team in any given month.
The physicians who sold in early rounds and held equity in the platform will likely do well financially when the exit comes. The physicians who joined later, through smaller tuck-in acquisitions with less favorable equity terms, are in a different position. And the wound care nurses who kept the chairs full during the holding period rarely get a check at all when the platform sells.
